All Blogs

Apr 09, 2024

ASTX295 is a novel small molecule antagonist of human Murine Double Minute 2 (MDM2), which tightly regulates the level and activity of the p53 tumor suppressor. According to the data presented at the AACR 2024 conference, the study enrolled 83 participants across 14 cohorts, investigating various dosing regimens an...

Apr 09, 2024

Triple-negative breast cancer (TNBC) accounts for 15–20% of incident breast cancers and is the only breast cancer (BC) subtype lacking targeted treatments. It is a biologically aggressive tumor characterized by moderate/high grade and highly proliferative cancer cells, which, together with limited treatment options...

Apr 09, 2024

At the American Association for Cancer Research (AACR) Annual Meeting 2024, significant findings from the Phase I/II PETRA trial, led by researchers at The University of Texas MD Anderson Cancer Center, were presented. The trial focused on evaluating the first-in-class PARP1-selective inhibitor, saruparib, in patie...

Apr 09, 2024

P-BCMA-ALLO1 is a novel investigational BCMA-targeted allogeneic, T stem cell memory (TSCM)-rich chimeric antigen receptor T-cell (CAR-T) therapy manufactured from healthy donor T-cells and available off-the-shelf. The findings presented at the AACR 2024 demonstrated that around 60% of patients (3 out of 5) with RR...

Apr 09, 2024

The treatment landscape for locally advanced Head and Neck Squamous Cell Carcinoma (HNSCC) presents a challenge, with conventional approaches such as surgery, radiation, and chemotherapy offering modest success rates. Despite these interventions, less than half of patients achieve disease-free status at 2 years, an...

Apr 09, 2024

Enhertu Receives US Approval as First HER2-focused Treatment for Metastatic Solid Tumors, Independent of Tumor Origin AstraZeneca and Daiichi Sankyo's drug Enhertu (trastuzumab deruxtecan) has gained approval in the United States for treating adult patients with inoperable or metastatic HER2-positive (IHC 3+) so...

Apr 08, 2024

Non-melanoma skin cancer (NMSC) is the most common post-transplant malignancy in solid organ transplant (SOT) recipients and occurs at a 7–53x higher incidence vs. the general population. Additionally, the optimal management of NMSC in SOT is not well established. RP1 is an oncolytic immunotherapy (HSV-1) that expr...

Apr 08, 2024

Regeneron Pharmaceuticals unveiled promising results from the Phase I/II LINKER-MM1 trial of linvoseltamab in patients grappling with relapsed/refractory (R/R) multiple myeloma (MM) during the oral plenary session at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego. Linvoselta...

Apr 08, 2024

After Johnson & Johnson reversed its decision last year regarding the acquisition of Tryvio (aprocitentan) in 2017, the original manufacturer of the hypertension treatment drug, Idorsia Pharmaceuticals has successfully guided the drug through the FDA approval process. The company stated that Tryvio, its endo...

Apr 08, 2024

Cancer vaccines represent a novel approach in cancer treatment, leveraging the body's immune system to identify and eradicate cancer cells. Unlike traditional vaccines that prevent infectious diseases, cancer vaccines aim to stimulate an immune response against specific proteins found on cancer cells, potentially p...